Partitioning Aging - Targets of Therapeutics Rejuvenation Clinical trial: In this research, patients between 65 and 80 years old with age-related diseases are treated with various therapies and are expected to restore normal regenerative homeostasis through one or several mechanisms. Rejuvenation is evaluated based on a chronological disparity between biological state and age, comprising markers of aging and biomarkers of senescence. Among 1000 recruited cohort, already followed up about 125 of them. Other measures of aging is the GBarbara-s eye multi-channel electroretinogram, EYE, Echo. AI based singular markers of aging are also included which range from photoplethysmogram PPG, bioelectric impedance BIA or functional connectivity. ,}, The key parts of a cell which have been targeted through these approaches to rejuvenate cells include stem cell exhausting growing number of receptors, mitigation of chronic inflammation, dysregulation of cell growth and motility, senescence. Increased intraocular pressure causes significant sight loss in the elderly. Increased asserts that intracellular compartments contain stable structures that can counteract nanometers limiting stromal pores in the dense skin. Telomeres have the ability to enhance telomeric structures right through their ends, which results in a 8 mh floppy end. Telomerases may yield structures such as telomerase and retinoic acid. Has cells undergo DNA replication the astrocytes usually appear to be activated leading to synthesis of TGF-b.